Introduction {#S1}
============

Gastric cancer is one of the main causes of cancer-related death worldwide and most patients are often diagnosed at locally advanced stages.^[@R1],[@R2]^ In these cases, radical surgery remains the mainstay for cure. However, the elevated rates of recurrence mean that late stage gastric cancer is difficult to cure by surgery alone.^[@R3]--[@R7]^ Therefore, combination therapy has become an established treatment, whereas the high risk of locoregional relapse has favored the inclusion of radiotherapy as a perioperative component of its comprehensive therapeutic strategy.

Radiation as single modality {#S2}
============================

Radiotherapy alone as adjuvant treatment was first explored in 1989 by the British Stomach Cancer Group.^[@R8]^ In that trial, gastric cancer patients from 10 centers throughout the United Kingdom were randomly allocated to receive surgery alone, surgery plus postoperative chemotherapy (mitomycin C, adriamycin and 5-FU), or postoperative radiotherapy with a defined dose of 45 Gy. No survival advantage was shown for those patients receiving either adjuvant therapy compared to those undergoing surgery alone after at least five years follow up.^[@R9]^ Similarly, no benefit for intraoperative radiotherapy (*i.e.*, single application of 28 Gy to the celiac axis) was seen in a German randomized trial conduced by Krämling *et al.*^[@R10]^

In 1998, Zhang *et al.*^[@R11]^ also initially evaluated the use of preoperative radiotherapy alone in Chinese patients with adenocarcinoma of the gastric cardia. In their prospective randomized trial, the authors reported increased resection rates and downstaging favoring the neoadjuvant radiotherapy. Operative mortality rates were reported to be 0.6% *versus* 2.5% with 10-year survival rates of 20.26% *versus* 13.30% for preoperative radiotherapy *versus* surgery alone, respectively. In contrast, two Russian studies published by Skoropad *et al.*^[@R12],[@R13]^ reported that neoadjuvant radiotherapy seems not to be sufficient to improve survival in gastric cancer patients. However, the results were promising in selected subgroups of patients treated with a combined preoperative plus intraoperative radiation protocol. A marked survival advantage was seen in subset analysis of lymphnode involvement (P=0.04) and extragastric tumor extension (P=0.042).^[@R12]^ In both trials, neoadjuvant radiotherapy was described as well tolerated and it has, therefore, been considered an important area of research for future refinement of adjuvant treatment in North American settings. The main results of these trials are summarized in [Table 1](#T1){ref-type="table"}.

Table 1Summary of results from main trials exploring radiation as single modality.TrialsYearTreatment armsNo.5-year survival (%)CommentsBritish Stomach Cancer Group^[@R8],[@R9]^1989/94Surgery only14520NS (P=0.14)External adjuvant RT15312Adjuvant chemoterapy13819Krämling *et al.*^[@R10]^1996Surgery only64NRMean survival 30.8 *vs* 26.9 months (NS)Intraoperative RT51NRZhang *et al.*^[@R11]^1998Surgery only19920.3Tumors from gastric cardiaNeoadjuvant RT17130.110-year survival of 13.3% *vs.* 19.7%; (P=0.009)Skoropad *et al.*^[@R12]^2000Surgery only5343Estimated from survival curveNeoadjuvant and operative RT5944Skoropad *et al.*^[@R13]^2002Surgery only753010-year survival of 32% *vs* 18%; NS (P=0.55)Neoadjuvant RT7739[^3]

Postoperative chemoradiation {#S3}
============================

In order to increase the effectiveness of radiation on tumor cells and, therefore, improve outcomes, radiotherapy has mainly been used in combined chemoradiation regimens. The Mayo Clinic performed the first trial to present significant results favoring the use of postoperative chemoradiotherapy *versus* surgery alone.^[@R14]^ This study enrolled 62 patients and local control was achieved in 61% of patients treated with adjuvant chemoradiation *versus* 45% in the surgery-alone group, while the 5-year survival also favored the adjuvant therapy group (20% *vs* 4%). However, this study has been criticized because randomization took place before patient consent for the study had been obtained, and 25% of patients refused treatment. The patients who refused treatment actually had the best survival of all groups (30% of 5-year survival). Furthermore, there was a high rate of discontinuation of treatment due to local side effects from radiotherapy.

Chemoradiotherapy had been occasionally used in the treatment of gastric cancer up to 2001,^[@R15]^ when the results of the INT-0116 trial showed an improvement in disease-free (DFS) and overall (OS) survival by chemoradiation with a significant impact on tumor management.^[@R3]^ Based on these data, there has been an increasing interest in radiotherapy and its association with chemotherapy for patients with locoregional disease as a part of adjuvant treatment after surgery in high-risk patients.^[@R15],[@R16]^

Major changes in adjuvant therapy for gastric cancer favoring chemoradiation followed the results of the INT-0116 trial.^[@R3]^ Since publication of this study, in the USA, the use of postoperative chemoradiation in stomach cancer has been considered a standard of care.^[@R17]^ Its original regimen utilized two cycles of 5-FU and leucovorin followed by concurrent chemoradiotherapy with 45 Gy of radiation administered using fields encompassing the entire gastric bed, regional nodes, and 2 cm proximal and distal margin. As far as the efficacy of combined therapy is concerned, this study demonstrated that patients treated with postoperative radiochemotherapy showed significantly better 3-year OS (50% *vs* 41%; P=0.005) as well as 3-year DFS survival (48 *vs* 31%; P=0.001) than those who were only treated with surgery.^[@R3]^ After over ten years of follow up, chemoradiation demonstrates continued benefit in terms of OS and DFS, and hazard ratios remain virtually unchanged since the original report. The authors also pointed out that subset analyses show robust treatment benefit in most subsets, with the exception of patients with diffuse histology.^[@R18]^ Nevertheless, the biggest benefit from chemoradiation was seen in those patients with higher N stages and limited lymph node dissection.

The main criticisms of the INT-0116 trial relate to the high toxicity of this regimen and the low quality of the surgery performed. In this study, 41% of patients had grade 3 toxicity and 32% had grade 4, while 31% did not complete treatment due to toxicity. Furthermore, the other main weakness of this trial was that only 10% of patients included in the analysis had undergone a formal D2-lymphadenectomy. A D1-dissection had been performed in 36%, but most patients (54%) had undergone a D0-dissection, which is less than a complete dissection of the N1 nodes.^[@R3]^ Therefore, some questions remain unanswered about the toxicity of this approach and its efficacy after adequate surgery.^[@R15],[@R19]^

Whether chemoradiation may contribute to improve outcomes after a D2-dissection was initially explored in two observational Asian studies.^[@R20],[@R21]^ In a Korean study, 544 patients received postoperative chemoradiation according to the INT-0116 protocol after curative D2-resection, and the results were compared with those of 446 patients who received surgery alone. The results showed a significantly prolonged median OS (95.6 *vs* 62.6 months; HR 0.80; P=0.02) and DFS survival (75.6 *vs* 52.7 months; HR 0.80; P=0.016) in the chemoradiation group. Three-year survival was 60% in the group treated with adjuvant chemoradiation.^[@R20]^ Accordingly, in a cohort study of 70 patients who received D2-dissection and adjuvant chemoradiation, Leong *et al.*^[@R21]^ reported 3-year OS, DFS, and local control of 60.6%, 54.1%, and 84.3%, respectively. However, as pointed out by Kwon *et al.*,^[@R22]^ different patient groups and radiation techniques to from those in the INT-0116 study were used. Also, all patients presented pathological stage T3--4 or node-positive disease, and a significant number of patients were treated with 3D conformal radiation.

Initially, a clinical trial conducted by Kwon and colleagues^[@R22]^ tried to evaluate the role of applying an adjuvant chemoradiotherapy regimen in the context of D2-dissection. Nevertheless, no conclusion could be drawn about the benefit of adding radiation to adjuvant chemotherapy because of the small sample size; this was due to early closure. The crude rate of locoregional relapse of the chemoradiation arm in this study was 12.9%, which was consistent with the results of the Korean^[@R20]^ and Singaporean^[@R21]^ studies previously cited (13% and 15%, respectively). Five-year DFS and OS were 70.1% and 76.2%, respectively, among patients treated with chemoradiation, but there was no statistically significant difference between the two groups. Additionally, these authors found no differences in clinical outcomes between the chemoradiation and chemotherapy treatment groups. Loco-regional failure tended to be less frequent in the chemoradiation group (12.9% *vs* 23.3%, P=0.335), but grade 3 and 4 neutropenia was also more common (48.4% *vs* 16.7%).^[@R22]^

Later, the Adjuvant Chemoradiation Therapy in Stomach Cancer (ARTIST) trial investigated the efficacy of postoperative chemoradiation as adjuvant treatment using a capecitabine plus cisplatin regimen in patients with gastric cancer who underwent curative D2-gastrectomy.^[@R23]^ After a median follow up of 53.2 months, the estimated 3-year DFS rates were 78.2% in the chemoradiation arm and 74.2% in the chemotherapy arm. Although there was no significant difference in DFS between the two treatment arms (P=0.0862), there was a statistically significant prolongation favoring the chemoradiation arm in positive pathological lymph node (P=0.0365) and the multivariate analysis demonstrated significantly increased DFS after adjustment for subgroup stages IB and II *versus* III and IV (HR 0.68; 95% CI: 0.473--0.995). Because these findings were from a subgroup analysis, the authors suggested these data should be interpreted with caution and planned a subsequent phase III trial (ARTIST-II) to compare chemotherapy *versus* chemoradiation in patients with D2-lymphadenectomy and pathological lymph node-positive disease in order to confirm the benefit of adjuvant chemoradiation.

In the ARTIST trial, treatment was completed as planned by 75.4% of patients in the chemotherapy arm *versus* 81.7% in the chemoradiation arm. Adverse events that led to treatment modifications (delays or dose reductions) occurred in 52% *versus* 35% of patients.^[@R23]^ In contrast, the study conduced by Kwon *et al.*^[@R22]^ utilized a protocol almost identical to the ARTIST trial, with the exception of using capecitabine/cisplatin rather than 5-FU/cisplatin as systemic chemotherapy. However, 27% of their patients were unable to complete all planned therapies due to toxicity, and the overall rates of grade 3--4 neutropenia in this study were 48.4%. These findings suggest that an adjuvant regimen employing 5-FU/cisplatin as the systemic component prior to and after concurrent chemoradiation with oral capecitabine is unacceptably toxic.

Very recently, Zhu *et al.*^[@R24]^ presented their phase III trial comparing postoperative intensity-modulated radiotherapy plus chemotherapy (IMRT-C) with chemotherapy only after a curative D2-dissection. Using a 5-FU/leucovorin chemotherapy regimen and a 45 Gy of IMRT radiation, grades 3 and 4 toxicities occurred in a small proportion of patients in both arms. There was no significant difference in 5-year OS between groups (48.4% *vs* 41.8%; P=0.122), but the chemoradiation arm experienced increased DFS (32 *vs* 50 months). While different forms of adjuvant chemotherapy are standards in Asia, a major criticism of this study is that more effective cytotoxic regimens are currently available for treatment of gastric cancer patients.

The benefit of adding radiotherapy to adjuvant chemotherapy was also explored in phase III trials by Bamias *et al.*^[@R25]^ and Kim *et al.*^[@R26]^ The former observed that neither local recurrence rates (10% *vs* 5%) nor 3-year OS or DFS were significantly improved by addition of radiation to platinum/docetaxel chemotherapy (61% *vs* 57% and 51% *vs* 48%, respectively).^[@R25]^ Applying a chemoradiation regimen basically identical to those used in the INT--0116 protocol for stage III and IV(M0) patients, Kim and colleagues^[@R26]^ observed that addition of radiation to the 5-FU/leucovorin regimen significantly improved locoregional recurrence-free survival, but not DFS. Unfortunately, both trials were terminated early.

Reporting their 10-year experience with adjuvante chemoradiation for resected gastric cancer, Chang *et al.*^[@R27]^ found that radiotherapy techniques were important prognostic factors, emphasizing the need for more sophisticated radiotherapy techniques to optimize the therapeutic ratio. These authors also emphasized that 35% of the radiotherapy planned in the INT--0116 study deviated from the protocol, reflecting the inadequacies of conventional techniques in targeting delineation. Equally, Leong and colleagues pointed out that 35% of radiotherapy treatment plans contained protocol deviations that could have been satisfactorily amended before commencement of treatment by using precisely defined, multiple-field, 3-D conformal techniques.^[@R28]^ In spite of this, even with conformal radiotherapy, chemoradiation regimens have also been associated with significant toxicity,^[@R22],[@R29]^ which is possibly influenced by the different chemotherapies delivered.^[@R22]^

Attempts to improve the chemoradiation regimens were recently reported in the CALGB 80101 trial that combined modern regimens of perioperative chemoterapy with fluoropyrimidine-based radiotherapy. Preliminary results of this study were presented at the 2011 American Society of Clinical Oncology (ASCO) annual meeting.^[@R30]^ Accordingly, the authors reported that postoperative chemoradiation using ECF before and after 5-FU/radiation did not improve survival when compared to bolus 5-FU/leucovorin before and after 5-FU/radiation. Thus, the original INT-0116 5-FU/leucovorin regimen remains standard for adjuvant chemoradiation. Results from the main phase III trials exploring chemoradiation approaches for gastric cancer are summarized in [Table 2](#T2){ref-type="table"}.

Table 2Summary of results from main phase III trials of chemoradiation therapy in 546 gastric cancer patients.TrialsNo.HR for OS (95% CI)HR for DFS (95% CI)Major toxicities (%)CommentsDeathNeutropenia (≥gr 3)INT-0116^[@R3],[@R18]^1.32 (1.10-1.60)1.51 (1.25-1.83)Recently up-dated5-FU/LV/RT281154Surgery only275\--ARTIST^[@R23]^NRNR3-year DFS 78.2% *vs* 74.2%XP/XRT/XP2300.448.4XP2280.440.7Zhu *et al.*^[@R24]^1.24 (0.94-1.65)1.35 (1.03-1.78)IMRT5-FU/LV/RT18607.55-FU/LV16507.3CALGB 80101^[@R30]^1.03 (0.80-1.34)1.00 (0.79-1.27)Not published in full5-FU/LV/RTNR^[\*](#TF2-1){ref-type="table-fn"}^353ECF/RTNR\<148[^4][^5]

Finally, despite the fact that perioperative chemotherapy (neoadjuvant and adjuvant) is an estabilished treatment for locally advanced tumors in many European countries, the ongoing CRITICS^[@R31]^ trial is currently open to recruitment in The Netherlands. This study aims to evaluate the theoretical advantages of adding radiotherapy to this approach. Since locoregional failure rates in patients with locally advanced resectable gastric cancer are quite high, it seems that the results of this trial will strengthen the need for radiation therapy as an integral part of their treatment.^[@R32]^ Its multicenter randomized phase III protocol investigates whether chemoradiotherapy (45 Gy in 5 weeks with daily cisplatin and capecitabine) after preoperative chemotherapy (3xepirubicin, cisplatin, capecitabine, ECC) and adequate (D1+) surgery leads to improved survival in comparison with postoperative chemotherapy (3×ECC).

Preoperative chemoradiation {#S4}
===========================

Neoadjuvant treatments have received increasing attention in the current multidisciplinary treatment model of locally advanced gastric cancer, especially since this approach may improve patient tolerance given that surgery-related morbidity and symptoms usually have a negative impact on performance status. In addition, the preoperative approach can result in a downstaging of the tumors that consequently might improve the curative resection rate in patients with advanced T and N stage disease.

Unfortunately, there is currently no phase III study supporting a purely neoadjuvant strategy of chemoradiation for operable gastric cancer. Stahl *et al.*^[@R33]^ tried to address the important concern of whether preoperative *versus* postoperative chemoradiation improves patient survival in gastric cancer; but their trial was prematurely stopped due to insufficient accrual and failed to provide a definitive anwer. The authors in this trial randomly allocated patients with locally advanced (uT3--4NXM0) adenocarcinoma of the esophagogastric junction to induction chemotherapy followed by surgery or chemotherapy followed by chemoradiotherapy plus surgery. There was no difference in the number of patients undergoing complete tumor resection between treatment groups (69.5% *vs* 71.5%); however, patients in the chemoradiation arm had a significantly higher probability of showing pathological complete response (15.6% *vs* 2.0%) or tumor-free lymph nodes (64.4% *vs* 37.7%) at resection. Also, there was no significant increase in postoperative mortality in the chemoradiotherapy group (10.2% *vs* 3.8%; P=0.26), which improved 3-year survival rate from 27.7% to 47.4% (P=0.07). Similarly, the design of the ongoing *Treatment of Gastric Cancer with Chemotherapy and Chemoradiotherapy* trial (TRACE) has the potential to verify the theoretical advantages of induction chemoradiation over the postoperative approach (NCT00512304).

Most of the available data concerning preoperative chemoradiation are currently coming from institutional phase II trials. In these settings, the experience from the MD Anderson Cancer Center has demonstrated that this comprehensive treatment is well tolerated and leads to appropriate pathological outcomes.^[@R34],[@R35]^ The results of these trials are important in the design of future prospective studies and open up interesting new pathways to upcoming protocols for the use of preoperative chemoradiation in gastric cancer.

Final comments {#S5}
==============

The policy of surgery alone for locally advanced gastric cancer has been abandoned, but an optimal multimodal and comprehensive therapeutic strategy has not yet been established. Efforts should, therefore, be made to accurately select patients to receive a combined treatment approach. Given this, the current medical literature has mainly supported the use of chemoradiation as an IMRT technique after curative resection in patients with positive lymph node status, postoperative residual tumor or close/positive margins, more advanced stages, and limited lymph node dissection (D0 and D1), especially for those who did not receive neoadjuvant chemotherapy.^[@R23],[@R27],[@R32],[@R36]--[@R41]^ In these settings, the ratio between metastatic and examined lymph nodes (N-ratio)^[@R42]--[@R46]^ might improve patient selection after an appropriated D2-gastrectomy,^[@R47]^ whereas the benefit of chemoradiation appeared to increase in line with higher N stages.^[@R18]^ Furthermore, combined chemoradiation may be considered for patients with initially unresectable gastric cancer. A possible way to improve the efficacy of adjuvant chemoradiation would be to integrate modern radiotherapy techniques with newer chemotherapy agents.
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